Updated vaccine expected to have 'important role' in protecting people from COVID-19 this winter
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, Aug. 15, 2022 (HealthDay News) -- A COVID-19 booster that is targeted to the omicron variant will be available soon -- and it has already been approved in Britain.
The U.K. Medicines and Healthcare Regulatory Agency was the first to give the go-ahead for the vaccine that was designed to fight both the original COVID-19 virus from 2020 and the omicron BA.1 variant, which began spreading last November, the Associated Press reported.
Health officials in the United Kingdom have not decided whether the vaccine is part of its fall COVID-19 strategy, though British officials have said everyone aged 50 years and older will be able to get a fall booster shot.
This vaccine's side effects are said to be typically "mild and self-resolving," similar to the earlier Moderna booster. This update will have an "important role" in protecting people from COVID-19 this winter, Stephane Bancel, Moderna chief executive, said in a company statement.
Having a targeted booster is a similar approach to what public health officials have done in years past with influenza, with an adjusted vaccine that targets up to four strains of the flu. About 70 percent of most recent COVID-19 virus samples collected arise from the omicron subvariant BA.5, according to the World Health Organization.
Other countries may follow Britain, including the United States. The U.S. Food and Drug Administration said in June that updated boosters needed to have protection against omicron variants, the AP reported. In Germany, the health minister said on Friday that the European Medicines Agency may clear the new vaccine in September.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles